July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
June 2025 in “Proceedings of the National Academy of Sciences” A PIK3CA mutation in Schwann cells causes severe nerve damage and increased glycolysis, but early treatment can help.
May 2025 in “Preprints.org” Unique microRNA patterns can help diagnose and treat severe alopecia areata.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
February 2025 in “Cureus” Early diagnosis and treatment of NCCAH can improve symptoms and fertility.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
December 2024 in “Journal of Investigative Dermatology” People with androgenetic alopecia had milder COVID-19 symptoms during the Omicron wave in China.
November 2024 in “Journal of Cutaneous and Aesthetic Surgery” Combining platelet-rich plasma and minoxidil can effectively regrow hair in severe alopecia areata cases.
November 2024 in “Journal of the Philippine Dermatological Society” Combining methotrexate and corticosteroids can effectively regrow hair in severe alopecia areata.
September 2024 in “Brazilian Journal of Case Reports” Clomiphene testing can help find ovarian causes of high testosterone in postmenopausal women.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
September 2024 in “LUTS Lower Urinary Tract Symptoms” People with hair loss may have worse urinary symptoms due to an enlarged prostate.
August 2024 in “Journal of Research in Clinical Medicine” COVID-19 can cause various skin issues, with some linked to how severe the illness is.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
June 2024 in “Journal of Psychiatry Spectrum” Iron deficiency can cause psychiatric symptoms that improve with proper treatment.
February 2024 in “Journal of Paediatrics and Child Health” Hormonal changes and social stress may link lupus and eating disorders in teens.
January 2024 in “Acta dermato-venereologica”
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
September 2023 in “Acta dermato-venereologica” Pilonidal sinus disease is linked to more severe hidradenitis suppurativa.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
June 2023 in “The journal of sexual medicine” The treatment helped a transgender woman stop drinking, improved her mental health, and reduced her gender dysphoria.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The TRPV3 channel structure changes linked to severe itch and hyperkeratosis were identified using cryo-EM.